BMS-986205 clinical trials at UC Health

• A Study of Experimental Combination Treatment with Chemotherapy, Nivolumab, and / or BMS-986205 for Bladder Cancer

  open to eligible people ages 18 years and up

  A study to evaluate nivolumab + chemotherapy or nivolumab/ BMS-986205 + chemotherapy followed by continued Immuno-Oncology therapy after radical cystectomy (RC) compared with neoadjuvant standard of care (SOC) chemotherapy alone in patients with muscle-invasive bladder cancer (MIBC)

  at UC Davis

Last updated: June 26, 2020